Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Gastroesophageal Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03505320
What this trial is testing

Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Who this might be right for
Pharmacokinetics of ZolbetuximabGastric CancerGastro-esophageal Junction (GEJ) Cancer+2 more
Astellas Pharma Global Development, Inc. 143
Testing effectiveness (Phase 2)Study completedNCT03196232
What this trial is testing

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaRecurrent Esophageal Carcinoma+4 more
George Albert Fisher 3
Early research (Phase 1)UnknownNCT05315830
What this trial is testing

HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Who this might be right for
Adenocarcinoma - GEJAdenocarcinoma of the Stomach
The First Affiliated Hospital of Bengbu Medical University 10
Early research (Phase 1)Study completedNCT02892123
What this trial is testing

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Who this might be right for
HER2-expressing Cancers
Jazz Pharmaceuticals 279
Testing effectiveness (Phase 2)Looking for participantsNCT06468280
What this trial is testing

Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer

Who this might be right for
Gastric CancerGastroEsophageal Cancer
Shanghai Zhongshan Hospital 84
Testing effectiveness (Phase 2)Study completedNCT04164979
What this trial is testing

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroEsophageal Cancer
University of California, Irvine 34
Early research (Phase 1)Looking for participantsNCT05365581
What this trial is testing

ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 398
Testing effectiveness (Phase 2)Active Not RecruitingNCT01142388
What this trial is testing

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Metastatic Esophageal AdenocarcinomaMetastatic Esophageal Squamous Cell CarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma+5 more
National Cancer Institute (NCI) 94
Large-scale testing (Phase 3)Looking for participantsNCT07118527
What this trial is testing

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 600
Early research (Phase 1)Looking for participantsNCT07705035
What this trial is testing

DBC-664 in Adult Patients With Solid Tumors

Who this might be right for
Malignant Germ Cell TumorLung AdenocarcinomaGastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma+3 more
Duboce Biopharmaceuticals, Inc. 210
Testing effectiveness (Phase 2)Active Not RecruitingNCT06188702
What this trial is testing

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

Who this might be right for
MTAP-deleted Solid Tumors
Servier Bio-Innovation LLC 60
Testing effectiveness (Phase 2)Ended earlyNCT05207722
What this trial is testing

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Celularity Incorporated 1
Early research (Phase 1)Study completedNCT03829436
What this trial is testing

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Who this might be right for
Hepatocellular CarcinomaMetastatic Castration Resistant Prostate CancerRenal Cell Carcinoma+9 more
Tempest Therapeutics 38
Large-scale testing (Phase 3)Active Not RecruitingNCT06356311
What this trial is testing

Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Who this might be right for
Gastroesophageal Cancer
Merck Sharp & Dohme LLC 450
Testing effectiveness (Phase 2)Looking for participantsNCT07488676
What this trial is testing

ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 150
Testing effectiveness (Phase 2)Looking for participantsNCT07622940
What this trial is testing

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Who this might be right for
Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech 36
Testing effectiveness (Phase 2)Looking for participantsNCT07127822
What this trial is testing

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

Who this might be right for
Gastric / Gastroesophageal Junction AdenocarcinomaMSI-H Cancer
Peking University 106
Testing effectiveness (Phase 2)Study completedNCT00032123
What this trial is testing

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal CancerGastric Cancer
SWOG Cancer Research Network
Testing effectiveness (Phase 2)Study completedNCT00268346
What this trial is testing

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal Cancer
Case Comprehensive Cancer Center 58
Testing effectiveness (Phase 2)Ended earlyNCT01123473
What this trial is testing

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionGastric Cancer
European Organisation for Research and Treatment of Cancer - EORTC 29
Next Page